Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

NCT00727532 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Low Accrual

Conditions

Hereditary Clear Cell Renal Cell Carcinoma
Kidney Cancer

Interventions

DRUG: Sorafenib

Sponsor

Northwestern University

Collaborators

[object Object]